Order Article Reprints

Barreto IV, Machado CB, Almeida DB, Pessoa FMCdP, Gadelha RB, Pantoja LdC, Oliveira DdS, Ribeiro RM, Lopes GS, de Moraes Filho MO, et al. Kinase Inhibition in Multiple Myeloma: Current Scenario and Clinical Perspectives. Pharmaceutics. 2022; 14(9):1784. https://doi.org/10.3390/pharmaceutics14091784

Barreto, Igor Valentim, Caio Bezerra Machado, Davi Benevides Almeida, Flávia Melo Cunha de Pinho Pessoa, Renan Brito Gadelha, Laudreísa da Costa Pantoja, Deivide de Sousa Oliveira, Rodrigo Monteiro Ribeiro, Germison Silva Lopes, Manoel Odorico de Moraes Filho, and et al. 2022. "Kinase Inhibition in Multiple Myeloma: Current Scenario and Clinical Perspectives" Pharmaceutics 14, no. 9: 1784. https://doi.org/10.3390/pharmaceutics14091784

Barreto, I. V., Machado, C. B., Almeida, D. B., Pessoa, F. M. C. d. P., Gadelha, R. B., Pantoja, L. d. C., Oliveira, D. d. S., Ribeiro, R. M., Lopes, G. S., de Moraes Filho, M. O., de Moraes, M. E. A., Khayat, A. S., de Oliveira, E. H. C., & Moreira-Nunes, C. A. (2022). Kinase Inhibition in Multiple Myeloma: Current Scenario and Clinical Perspectives. Pharmaceutics, 14(9), 1784. https://doi.org/10.3390/pharmaceutics14091784